The biotech firm Lysando AG with its subsidiary based in Regensburg ‘Lisandro GmbH’ & AiCuris Anti-infective Cures GmbH, a pioneering firm in the discovery & development of drugs against infectious diseases, made an announcement today regarding the signing of a strategic cooperation for the development & optimization of Artilysin(R)-based drug candidates for different anti-bacterial indications.
According to the terms of the agreement, AiCuris will be receiving exclusive access to Lysando’s Artilysin technology for generation of Artilysin(R) for certain treatments of gram-negative and gram-positive bacterial infections in humans. Both firms will be collaborating in the identification, as well as, optimization of new Artilysin(R)-based drug candidates to treat bacterial infections, inclusive of sepsis, hospital-acquired pneumonia, and cystic fibrosis. The agreement’s financial details weren’t disclosed.
The Chief Executive Officer of AiCuris, Doctor Holger Zimmermann stated that the position of AiCuris will be strengthened with this co-operation and it will be positioned as the leading pharma firm in anti-infective drug development. One of the biggest threats to human health all over the world is antimicrobial resistance and there is a definite need for innovation to address the high and increasing medical need.
He further said that today AiCuris is one of the few European firms active in that field & remains committed to combatting resistant bacteria & to the development of new antibacterial agents. With our supreme expertise in anti-infective drug development, AiCuris is best positioned and determined to drive the fight against the antimicrobial resistance with new approaches. Artilysin(R)s represent a novel class of molecules with a mechanism of action which is different from all known antimicrobial agents. We are highly looking forward to working with Lysando for the development of drug candidates with the prospect of actually making a difference in the treatment of infections with multidrug-resistant bacteria.